Abzena

Abzena is a contract research, development and manufacturing organization (CRDMO) delivering integrated drug discovery, development and manufacturing services to global pharmaceutical and biotech companies. The company focuses exclusively on the high-growth biologics and antibody-drug conjugate (ADC) end markets, with the ability to serve customers from early research through clinical trials and beyond.

Abzena operates three centers of excellence in the United Kingdom and the United States. The company’s end-to-end capabilities and strategically located network enable biopharma clients to bring life-changing therapies to patients more quickly and cost-effectively.

Current CEO: Matthew Stober

Headquarters: San Diego, CA

Investment Year: 2018

Fund: WCAS Fund XII